

## Symbicort<sup>®</sup> (budesonide/formoterol) – First-time generic

- On July 31, 2023, [Viatris and Kindeva](#) launched an [AB-rated](#) generic version ([Breyna™](#)) of AstraZeneca's [Symbicort \(budesonide/formoterol\)](#) metered-dose inhaler.
  - Previously, [Prasco](#) launched an authorized brand alternative of Symbicort in January of 2020.
- Symbicort is approved for the treatment of asthma in patients 6 years of age and older, and for the maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD) including chronic bronchitis and/or emphysema and to reduce exacerbations of COPD.
  - Symbicort 160/4.5 is the only strength indicated for the treatment of COPD.